These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 8843916)

  • 1. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
    Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis.
    Cheng CK; Berger AS; Pearson PA; Ashton P; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):442-53. PubMed ID: 7843913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
    Cardillo JA; Farah ME; Mitre J; Morales PH; Costa RA; Melo LA; Kuppermann B; Jorge R; Ashton P
    Br J Ophthalmol; 2004 Sep; 88(9):1201-5. PubMed ID: 15317716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.
    Yang CS; Khawly JA; Hainsworth DP; Chen SN; Ashton P; Guo H; Jaffe GJ
    Arch Ophthalmol; 1998 Jan; 116(1):69-77. PubMed ID: 9445210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy].
    Bi HS; Cui Y; Zhang JH; Wang XR; Xie XF
    Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):37-41. PubMed ID: 16638279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiproliferative effect of sustained drug delivery system of all-trans retinoic acid implant into rabbit's vitreous cavity for treatment of proliferative vitreoretinopathy].
    Yan XR; Dong XG; Chen N; Wang W
    Zhonghua Yan Ke Za Zhi; 2003 Oct; 39(10):621-5. PubMed ID: 14766078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy.
    Kuo HK; Chen YH; Wu PC; Kuo YH
    Ophthalmologica; 2015; 233(3-4):198-203. PubMed ID: 25721986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
    Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA
    Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Triamcinolone acetonide in the prevention of experimental proliferative vitreoretinopathy].
    Liang HC; Hui YN; Cai YS
    Zhonghua Yan Ke Za Zhi; 1994 Mar; 30(2):122-4. PubMed ID: 8001444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
    Ozerdem U; Mach-Hofacre B; Cheng L; Chaidhawangul S; Keefe K; McDermott CD; Bergeron-Lynn G; Appelt K; Freeman WR
    Curr Eye Res; 2000 Jun; 20(6):447-53. PubMed ID: 10980656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.
    Joondeph BC; Peyman GA; Khoobehi B; Yue BY
    Ophthalmic Surg; 1988 Apr; 19(4):252-6. PubMed ID: 3362494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits.
    Yasukawa T; Kimura H; Tabata Y; Miyamoto H; Honda Y; Ogura Y
    Graefes Arch Clin Exp Ophthalmol; 2002 Aug; 240(8):672-8. PubMed ID: 12192462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
    Alikacem N; Yoshizawa T; Nelson KD; Wilson CA
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR.
    Giordano GG; Refojo MF; Arroyo MH
    Invest Ophthalmol Vis Sci; 1993 Aug; 34(9):2743-51. PubMed ID: 8344796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
    Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
    Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of triamcinolone acetonide following intravitreal injection in New Zealand white rabbits.
    McGee DH; Dembinska O; Gruebbel MM
    Int J Toxicol; 2005; 24(6):419-25. PubMed ID: 16393934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin-ricin A chain toxin limits the development of experimental proliferative vitreoretinopathy.
    Handa JT; Keithahn MA; Jaffe GJ
    Exp Eye Res; 1996 Jun; 62(6):689-96. PubMed ID: 8983950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.
    Chen EP; Steinhorst UH; Samsa GP; Saloupis PT; Hatchell DL
    Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2160-4. PubMed ID: 1607226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravitreal triamcinolone acetonide in the treatment of experimental Staphylococcus epidermidis endophthalmitis.
    Hosseini H; Mehryar M; Eghtedari M; Ahmadi F; Nowroozizadeh S
    Curr Eye Res; 2009 Feb; 34(2):145-51. PubMed ID: 19219686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
    Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
    Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.